Printer Friendly

Carl Zeiss Meditec Receives FDA Clearance for Cirrus HD-OCT Software Version 4.0.

- New Anterior Segment Imaging, Normative Database and Change Analysis applications allow eye care professionals to identify disease and monitor progression with greater certainty -

DUBLIN, Calif. -- A new suite of optical coherence tomography (OCT) software applications for the Cirrus[TM] HD-OCT has been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution. The Cirrus HD-OCT 4.0 with Retinal Nerve Fiber Layer and Macular Normative Databases is indicated for in-vivo viewing, axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.

"Throughout our 15 year history of OCT innovation, we have seen its utility evolve from imaging of the retina to now offering both posterior and anterior capabilities," said Michael Kaschke, PhD, President and Chief Executive Officer of Carl Zeiss Meditec. "The Cirrus HD-OCT 4.0 incorporates the latest applications to provide eye care professionals with the tools and analyses needed to manage complex eye conditions throughout a patient's lifetime."

New Tools for Glaucoma Management

With the most robust features for RNFL assessment available in an OCT platform, even subtle abnormalities and changes can be identified between patient visits. Cirrus HD-OCT Version 4.0 offers three tools for quantified glaucoma assessment and management:

* RNFL Normative Database helps to identify retinal nerve fiber layer (RNFL) loss.

* Anterior Segment Imaging provides visualization of the angle and measurement of central corneal thickness.

* Guided Progression Analysis[TM] (GPA) software supports glaucoma treatment decision-making by identifying statistically significant changes in RNFL thickness.

"Cirrus 4.0 takes OCT imaging to a whole new level," said Ike K. Ahmed, MD, FRCSC, Assistant Professor at the University of Toronto. "The GPA and anterior segment imaging capabilities give me increased confidence in determining whether or not my glaucoma patients are responding adequately to therapy or if they require further intervention."

Cirrus HD-OCT RNFL measurements have set a new standard in reproducibility. According to a recent study in British Journal of Ophthalmology, reproducibility of Cirrus HD-OCT RNFL thickness measurements is within a standard deviation of 1.2 om for glaucomatous patients1.

Advanced Retina Features

New enhancements to help clinicians better manage retinal diseases and monitor patient response to therapy are also included in Cirrus HD-OCT Version 4.0:

* Macular Change Analysis helps physicians evaluate retinal status and response to therapy by mapping changes in macular thickness.

* Fovea Finder automatically identifies the center of the fovea to ensure the accuracy of macular thickness measurements.

* Macular Thickness Normative Data allows physicians to identify retina disease based on comparison to age-matched data.

"The new Fovea Finder is a one-of-a-kind feature that obtains the precise location of each patient's fovea as a baseline for future scans and for visual comparison of images from one appointment to the next," said Iris Wang, MD, former Research Fellow at Baskin Palmer Eye Institute in Miami, FL. "The superb reproducibility of images along with highly sensitive macular change analysis data allows me to make more informed treatment decisions and to more closely evaluate the benefits of therapy."

Cirrus-HD OCT software version 4.0 is DICOM compatible for use with Carl Zeiss Meditec's connectivity solutions, including VISUPAC Star, and EMR platforms.

"Carl Zeiss Meditec has played a big part in the evolution of OCT and we will continue to bring enhancements to the market in step with clinical advances to support our physician customers as well as growing patient demographics," Kaschke added.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies.

The Company supplies innovative technologies and application-oriented solutions which enable doctors to improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat ophthalmic diseases. In the field of Neuro/ENT surgery the Company provides innovative visualization solutions. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiotherapy.

The Company's around 2,100 employees generated revenue of about EUR 600 million in fiscal year 2007/08 (ended Sept. 30). The headquarters of Carl Zeiss Meditec are located in Jena, Germany. In addition to other subsidiaries in Germany, the Company is represented by over 50 percent of its employees at sites in the USA, Japan, Spain and France.

Thirty-five percent of Carl Zeiss Meditec's shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups engaged in the optical and opto-electronics industry. The five independently run business segments of Carl Zeiss AG operate in the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". Carl Zeiss AG is headquartered in Oberkochen, Germany. During fiscal year 2007/08 (ended Sept. 30) the company generated revenues of about EUR 2.7 billion. Carl Zeiss has around 13,000 employees in more than 30 countries, including more than 8,000 in Germany.

For further information please visit our website at:

1 Vizzeri G, Weinreb RN, Gonzalez-Garcia A, Bowd C, Medeiros FA, Sample PA, Zangwill LM. Agreement between Spectral-Domain and Time-Domain OCT for measuring RNFL thickness. British Journal of Ophthalmology. 2009 Mar 19.
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Company overview
Date:Jun 9, 2009
Previous Article:Research and Markets: World Auto Report Reveals - China Becomes the World's Second Largest Market after the USA after Selling 9.2 Million Units.
Next Article:PC Laptops Founder & President, Dan Young, Named to Microsoft's Partner Advisory Council.

Related Articles
Measuring software.
Final preparations for NEC as Optrafair opening nears.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters